{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:48:37Z","timestamp":1760298517461},"reference-count":200,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1097\/mjt.0b013e318247148f","type":"journal-article","created":{"date-parts":[[2012,5,5]],"date-time":"2012-05-05T15:58:12Z","timestamp":1336233492000},"page":"228-246","source":"Crossref","is-referenced-by-count":18,"title":["Bisphosphonates"],"prefix":"10.1097","volume":"19","author":[{"given":"Tommaso","family":"Iannitti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Rosini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Rottigni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beniamino","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210202","doi-asserted-by":"crossref","first-page":"13361","DOI":"10.1073\/pnas.95.23.13361","article-title":"Bone homeostasis.","volume":"95","author":"Rodan","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R2-11-20210202","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.0105-2896.2009.00857.x","article-title":"Bone remodeling in rheumatic disease: a question of balance.","volume":"233","author":"Walsh","year":"2010","journal-title":"Immunol Rev"},{"key":"R3-11-20210202","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jbspin.2006.06.005","article-title":"Extra-skeletal effects of bisphosphonates.","volume":"74","author":"Corrado","year":"2007","journal-title":"Joint Bone Spine"},{"key":"R4-11-20210202","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1359\/jbmr.2000.15.10.2042","article-title":". Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats.","volume":"15","author":"Li","year":"2000","journal-title":"J Bone Miner Res"},{"key":"R5-11-20210202","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":". Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R6-11-20210202","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/jbmr.182","article-title":". Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.","volume":"25","author":"Li","year":"2010","journal-title":"J Bone Miner Res"},{"key":"R7-11-20210202","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1359\/JBMR.050712","article-title":". Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model.","volume":"20","author":"Little","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R8-11-20210202","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.bone.2007.01.015","article-title":". Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys.","volume":"40","author":"Manabe","year":"2007","journal-title":"Bone"},{"key":"R9-11-20210202","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bone.2008.05.019","article-title":". Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.","volume":"43","author":"McDonald","year":"2008","journal-title":"Bone"},{"key":"R10-11-20210202","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bone.2011.07.020","article-title":". Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells.","volume":"49","author":"Cornish","year":"2011","journal-title":"Bone"},{"key":"R11-11-20210202","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/8756-3282(96)00182-2","article-title":". Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones.","volume":"19","author":"Masarachia","year":"1996","journal-title":"Bone"},{"key":"R12-11-20210202","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":". Intravenous zoledronic acid in postmenopausal women with low bone mineral density.","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"R13-11-20210202","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.091201","article-title":"Atrial fibrillation and bisphosphonate therapy.","volume":"25","author":"Pazianas","year":"2010","journal-title":"J Bone Miner Res"},{"key":"R14-11-20210202","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","article-title":"Therapeutic approaches to bone diseases.","volume":"289","author":"Rodan","year":"2000","journal-title":"Science"},{"issue":"Pt 7","key":"R15-11-20210202","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1242\/jcs.063032","article-title":". Bone remodelling at a glance.","volume":"124","author":"Crockett","year":"2011","journal-title":"J Cell Sci"},{"key":"R16-11-20210202","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10439-005-8964-9","article-title":". The effects of trabecular-bone loading variables on the surface signaling potential for bone remodeling and adaptation.","volume":"33","author":"Ruimerman","year":"2005","journal-title":"Ann Biomed Eng"},{"key":"R17-11-20210202","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ar.1092260402","article-title":"Skeletal structural adaptations to mechanical usage (SATMU): 1. Redefining Wolffs law: the bone modeling problem.","volume":"226","author":"Frost","year":"1990","journal-title":"Anat Rec"},{"key":"R18-11-20210202","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/ar.1092260403","article-title":"Skeletal structural adaptations to mechanical usage (SATMU): 2. Redefining Wolffs law: the remodeling problem.","volume":"226","author":"Frost","year":"1990","journal-title":"Anat Rec"},{"key":"R19-11-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00675618","article-title":"Suggested fundamental concepts in skeletal physiology.","volume":"52","author":"Frost","year":"1993","journal-title":"Calcif Tissue Int"},{"issue":"Pt 8","key":"R20-11-20210202","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1242\/jcs.108.8.2729","article-title":"The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure.","volume":"108","author":"Vaananen","year":"1995","journal-title":"J Cell Sci"},{"issue":"Pt 3","key":"R21-11-20210202","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1242\/jcs.113.3.377","article-title":". The cell biology of osteoclast function.","volume":"113","author":"Vaananen","year":"2000","journal-title":"J Cell Sci"},{"key":"R22-11-20210202","first-page":"128","article-title":"Biological underpinnings of Frosts mechanostat thresholds: the important role of osteocytes.","volume":"10","author":"Hughes","year":"2010","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"R23-11-20210202","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1007\/s00018-010-0479-3","article-title":"Cellular communications in bone homeostasis and repair.","volume":"67","author":"Nakahama","year":"2010","journal-title":"Cell Mol Life Sci"},{"issue":"Suppl 1","key":"R24-11-20210202","first-page":"S147","article-title":". ASBMR 29th annual meeting: Lacunocanalicular fluid flow and regulation of basic multicellular unit activity.","volume":"22","author":"Goulet","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R25-11-20210202","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ejo\/12.1.81","article-title":"Update on bone cell biology.","volume":"12","author":"Arnett","year":"1990","journal-title":"Eur J Orthod"},{"key":"R26-11-20210202","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jcp.2007.048868","article-title":". The cell biology of bone metabolism.","volume":"61","author":"Datta","year":"2008","journal-title":"J Clin Pathol"},{"key":"R27-11-20210202","first-page":"411","article-title":"Basic bone cell biology.","volume":"74","author":"Freemont","year":"1993","journal-title":"Int J Exp Pathol"},{"key":"R28-11-20210202","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0950-3579(05)80071-8","article-title":"The cell biology of bone.","volume":"7","author":"MacDonald","year":"1993","journal-title":"Baillieres Clin Rheumatol"},{"key":"R29-11-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/aja.1001830102","article-title":"Bone cell biology: the regulation of development, structure, and function in the skeleton.","volume":"183","author":"Marks","year":"1988","journal-title":"Am J Anat"},{"key":"R30-11-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0950-351X(88)80006-5","article-title":"Cell biology of bone.","volume":"2","author":"Martin","year":"1988","journal-title":"Baillieres Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"R31-11-20210202","first-page":"S131","article-title":"The cell biology of bone growth.","volume":"48","author":"Price","year":"1994","journal-title":"Eur J Clin Nutr"},{"key":"R32-11-20210202","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.molmed.2008.04.001","article-title":"Molecular mechanisms of inflammatory bone damage: emerging targets for therapy.","volume":"14","author":"Herman","year":"2008","journal-title":"Trends Mol Med"},{"key":"R33-11-20210202","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00223-002-1049-y","article-title":"Inflammatory mediators as essential elements in bone remodeling.","volume":"73","author":"Goldring","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"R34-11-20210202","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S8756-3282(03)00213-8","article-title":". Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.","volume":"33","author":"Nagata","year":"2003","journal-title":"Bone"},{"key":"R35-11-20210202","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1084\/jem.185.6.1005","article-title":". Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocytemacrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation.","volume":"185","author":"Udagawa","year":"1997","journal-title":"J Exp Med"},{"key":"R36-11-20210202","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/bbrc.2001.4380","article-title":". Interleukin-18 up-regulates osteoprotegerin expression in stromalosteoblastic cells.","volume":"281","author":"Makiishi-Shimobayashi","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"R37-11-20210202","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4049\/jimmunol.175.2.917","article-title":"IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2 signaling.","volume":"175","author":"Mangashetti","year":"2005","journal-title":"J Immunol"},{"key":"R38-11-20210202","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1172\/JCI10530","article-title":"IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB.","volume":"107","author":"Abu-Amer","year":"2001","journal-title":"J Clin Invest"},{"key":"R39-11-20210202","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1074\/jbc.M104957200","article-title":". Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling.","volume":"277","author":"Wei","year":"2002","journal-title":"J Biol Chem"},{"key":"R40-11-20210202","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/1529-0131(200004)43:4<821::AID-ANR12>3.0.CO;2-T","article-title":". Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis.","volume":"43","author":"Romas","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R41-11-20210202","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/jbmr.5650110113","article-title":". Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.","volume":"11","author":"Kotake","year":"1996","journal-title":"J Bone Miner Res"},{"key":"R42-11-20210202","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0083-6729(06)74016-X","article-title":". The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation.","volume":"74","author":"Jacques","year":"2006","journal-title":"Vitam Horm"},{"key":"R43-11-20210202","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00198-010-1192-7","article-title":"The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis.","volume":"21","author":"Edwards","year":"2010","journal-title":"Osteoporos Int"},{"key":"R44-11-20210202","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2249.1998.00552.x","article-title":". Differential inhibitory effects of indomethacin, dexamethasone, and interferon-gamma (IFN-gamma) on IL-11 production by rheumatoid synovial cells.","volume":"112","author":"Taki","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"R45-11-20210202","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.1780391012","article-title":". The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis.","volume":"39","author":"Isomaki","year":"1996","journal-title":"Arthritis Rheum"},{"key":"R46-11-20210202","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":". IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.","volume":"103","author":"Kotake","year":"1999","journal-title":"J Clin Invest"},{"key":"R47-11-20210202","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI11176","article-title":". TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.","volume":"106","author":"Lam","year":"2000","journal-title":"J Clin Invest"},{"key":"R50-11-20210202","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/rheumatology\/22.1.22","article-title":"The effect of hyperparathyroidism on the course of rheumatoid arthritis.","volume":"22","author":"Crisp","year":"1983","journal-title":"Br J Rheumatol"},{"key":"R51-11-20210202","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1006\/bbrc.1999.1623","article-title":". Activated T lymphocytes support osteoclast formation in vitro.","volume":"265","author":"Horwood","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"R52-11-20210202","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","article-title":". Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"issue":"Suppl 2","key":"R53-11-20210202","doi-asserted-by":"crossref","first-page":"ii84","DOI":"10.1136\/ard.61.suppl_2.ii84","article-title":"Bone destruction in arthritis.","volume":"61","author":"Gravallese","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R54-11-20210202","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.0105-2896.2005.00338.x","article-title":". Rheumatic diseases: the effects of inflammation on bone.","volume":"208","author":"Walsh","year":"2005","journal-title":"Immunol Rev"},{"issue":"Suppl 1","key":"R55-11-20210202","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.joca.2010.01.015","article-title":"Effects of chondroitin sulfate in the pathophysiology of the osteoarthritic joint: a narrative review.","volume":"18","author":"Martel-Pelletier","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"key":"R56-11-20210202","first-page":"295","article-title":". The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.","volume":"26","author":"Kwan Tat","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"R57-11-20210202","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/ar148","article-title":"Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis.","volume":"3","author":"Sandell","year":"2001","journal-title":"Arthritis Res"},{"key":"R58-11-20210202","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11926-000-0019-5","article-title":". COX-2, NO, and cartilage damage and repair.","volume":"2","author":"Amin","year":"2000","journal-title":"Curr Rheumatol Rep"},{"key":"R59-11-20210202","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/rheumatology\/36.1.140","article-title":". Elevated serum C-reactive protein levels in osteoarthritis.","volume":"36","author":"Sharif","year":"1997","journal-title":"Br J Rheumatol"},{"key":"R60-11-20210202","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/art.1780400606","article-title":". Enhancement of cartilage matrix protein synthesis in arthritic cartilage.","volume":"40","author":"Okimura","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R61-11-20210202","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/ar630","article-title":"Aggrecanases and cartilage matrix degradation.","volume":"5","author":"Nagase","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"R62-11-20210202","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.3171\/FOC\/2008\/24\/1\/E3","article-title":"The pathogenesis of ankylosing spondylitis.","volume":"24","author":"Shamji","year":"2008","journal-title":"Neurosurg Focus"},{"key":"R63-11-20210202","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10067-006-0283-5","article-title":". Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis.","volume":"26","author":"Bal","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R64-11-20210202","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/ard.2003.011023","article-title":"Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review.","volume":"62","author":"Keller","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R65-11-20210202","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":". Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.","volume":"70","author":"Lie","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R66-11-20210202","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":". Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R67-11-20210202","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/rheumatology\/kel072","article-title":"Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).","volume":"45","author":"Kim","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R68-11-20210202","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1902\/annals.1998.3.1.108","article-title":"The pathobiology of periodontal diseases may affect systemic diseases: inversion of a paradigm.","volume":"3","author":"Page","year":"1998","journal-title":"Ann Periodontol"},{"key":"R69-11-20210202","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1084\/jem.173.5.1291","article-title":". Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells.","volume":"173","author":"Kodama","year":"1991","journal-title":"J Exp Med"},{"key":"R70-11-20210202","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1034\/j.1600-0765.2003.00615.x","article-title":". Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis.","volume":"38","author":"Crotti","year":"2003","journal-title":"J Periodontal Res"},{"issue":"Suppl 6","key":"R73-11-20210202","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1600-051X.2005.00785.x","article-title":"Host response modulation in the management of periodontal diseases.","volume":"32","author":"Salvi","year":"2005","journal-title":"J Clin Periodontol"},{"key":"R74-11-20210202","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1359\/jbmr.2002.17.2.210","article-title":". Periodontal ligament cells under mechanical stress induce osteoclastogenesis by receptor activator of nuclear factor kappaB ligand up-regulation via prostaglandin E2 synthesis.","volume":"17","author":"Kanzaki","year":"2002","journal-title":"J Bone Miner Res"},{"key":"R75-11-20210202","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.abb.2010.06.026","article-title":"Inflammatory bowel diseases, celiac disease, and bone.","volume":"503","author":"Bianchi","year":"2010","journal-title":"Arch Biochem Biophys"},{"key":"R76-11-20210202","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00054725-200002000-00002","article-title":". A simple classification of Crohns disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.","volume":"6","author":"Gasche","year":"2000","journal-title":"Inflamm Bowel Dis"},{"key":"R77-11-20210202","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2004.02.072","article-title":"From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation.","volume":"126","author":"Sands","year":"2004","journal-title":"Gastroenterology"},{"key":"R78-11-20210202","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00042737-199704000-00007","article-title":"Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group.","volume":"9","author":"Lennard-Jones","year":"1997","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R79-11-20210202","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11894-009-0073-8","article-title":"Natural history and complications of IBD.","volume":"11","author":"Vatn","year":"2009","journal-title":"Curr Gastroenterol Rep"},{"key":"R81-11-20210202","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1172-1-3","article-title":"Celiac disease.","volume":"1","author":"Holtmeier","year":"2006","journal-title":"Orphanet J Rare Dis"},{"key":"R82-11-20210202","first-page":"1508","article-title":"Chronic inflammatory intestinal diseases and bone loss.","volume":"54","author":"Bardella","year":"2005","journal-title":"Gut"},{"key":"R83-11-20210202","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/gut.2004.044370","article-title":". The RANKLOPG system is activated in inflammatory bowel disease and relates to the state of bone loss.","volume":"54","author":"Moschen","year":"2005","journal-title":"Gut"},{"key":"R84-11-20210202","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/j.1440-1681.2008.05053.x","article-title":"Endocrine regulation of calcium transport in epithelia.","volume":"35","author":"Khanal","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R85-11-20210202","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.mehy.2010.10.023","article-title":". Is there another possible approach to inhibit wear particles-induced inflammatory osteolysis.","volume":"76","author":"Liu","year":"2011","journal-title":"Med Hypotheses"},{"key":"R86-11-20210202","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jbm.b.30913","article-title":". Titanium particles that have undergone phagocytosis by macrophages lose the ability to activate other macrophages.","volume":"85","author":"Xing","year":"2008","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"R87-11-20210202","first-page":"S125","article-title":"Spinal implant debris-induced osteolysis. Spine (Phila Pa 1976).","volume":"28","author":"Hallab","year":"2003","journal-title":""},{"key":"R88-11-20210202","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1302\/0301-620X.79B3.0790467","article-title":". Aseptic loosening of total hip replacement. Macrophage expression of inducible nitric oxide synthase and cyclo-oxygenase-2, together with peroxynitrite formation, as a possible mechanism for early prosthesis failure.","volume":"79","author":"Hukkanen","year":"1997","journal-title":"J Bone Joint Surg Br"},{"key":"R89-11-20210202","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bpg.2010.07.006","article-title":"Primary biliary cirrhosis.","volume":"24","author":"Nguyen","year":"2010","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R90-11-20210202","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaut.2009.09.010","article-title":". Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis.","volume":"33","author":"Barak","year":"2009","journal-title":"J Autoimmun"},{"key":"R91-11-20210202","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0168-8278(02)00435-X","article-title":". High serum osteoprotegerin and low RANKL in primary biliary cirrhosis.","volume":"38","author":"Szalay","year":"2003","journal-title":"J Hepatol"},{"key":"R92-11-20210202","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/ALN.0b013e3181e3db38","article-title":"An update on the pathophysiology of complex regional pain syndrome.","volume":"113","author":"Bruehl","year":"2010","journal-title":"Anesthesiology"},{"key":"R93-11-20210202","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1007\/s11064-008-9711-z","article-title":"Intracellular signaling in primary sensory neurons and persistent pain.","volume":"33","author":"Cheng","year":"2008","journal-title":"Neurochem Res"},{"key":"R94-11-20210202","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00415-005-0737-8","article-title":"Complex regional pain syndrome.","volume":"252","author":"Birklein","year":"2005","journal-title":"J Neurol"},{"key":"R99-11-20210202","first-page":"288","article-title":". Anabolic effects and inhibition of interleukin 6 production induced by neridronate on human osteoblasts in Italian.","volume":"58","author":"Spreafico","year":"2006","journal-title":"Reumatismo"},{"key":"R100-11-20210202","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","article-title":". Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.","volume":"12","author":"Frith","year":"1997","journal-title":"J Bone Miner Res"},{"key":"R101-11-20210202","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bone.2003.07.007","article-title":". Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates.","volume":"33","author":"van Beek","year":"2003","journal-title":"Bone"},{"key":"R102-11-20210202","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","article-title":". Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.","volume":"264","author":"van Beek","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"R103-11-20210202","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/bbrc.1999.0224","article-title":"Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerasefarnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.","volume":"255","author":"van Beek","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"R104-11-20210202","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy.","volume":"360","author":"Weinstein","year":"2009","journal-title":"N Engl J Med"},{"key":"R105-11-20210202","first-page":"883","article-title":". Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial.","volume":"51","author":"Santra","year":"2010","journal-title":"Singapore Med J"},{"key":"R106-11-20210202","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jbspin.2010.05.010","article-title":". The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis.","volume":"78","author":"Kang","year":"2011","journal-title":"Joint Bone Spine"},{"key":"R107-11-20210202","first-page":"144","article-title":". Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy.","volume":"28","author":"Maksymowych","year":"2001","journal-title":"J Rheumatol"},{"key":"R108-11-20210202","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.10139","article-title":". A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.","volume":"46","author":"Maksymowych","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R109-11-20210202","first-page":"348","article-title":". Transient efficacy of pulse pamidronate treatment in active spondylarthropathies: an open study of 35 cases.","volume":"24","author":"Toussirot","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"R110-11-20210202","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/ard.2005.041392","article-title":". Treatment of ankylosing spondylitis with pamidronate: an open label study.","volume":"65","author":"Grover","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R111-11-20210202","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/ard.2004.022871","article-title":". An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover.","volume":"64","author":"Cairns","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R112-11-20210202","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10067-010-1378-6","article-title":". The synergistic efficacy of adalimumab and pamidronate in a patient with ankylosing spondylitis.","volume":"29","author":"Slobodin","year":"2010","journal-title":"Clin Rheumatol"},{"key":"R113-11-20210202","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/ard.2010.142539","article-title":". Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study.","volume":"70","author":"McQueen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R114-11-20210202","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jbspin.2010.11.015","article-title":"Bone disease in cystic fibrosis: whats new.","volume":"78","author":"Javier","year":"2011","journal-title":"Joint Bone Spine"},{"key":"R115-11-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-009-9316-9","article-title":". The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis.","volume":"86","author":"Paccou","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"R117-11-20210202","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.rdc.2006.07.004","article-title":"Inflammation-induced bone loss: can it be prevented.","volume":"32","author":"Romas","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"R118-11-20210202","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/1529-0131(200108)44:8<1908::AID-ART329>3.0.CO;2-4","article-title":". Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits.","volume":"44","author":"Ceponis","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R119-11-20210202","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K","article-title":". Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis.","volume":"43","author":"Barrera","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R120-11-20210202","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1023\/A:1016281608773","article-title":". Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro.","volume":"12","author":"Pennanen","year":"1995","journal-title":"Pharm Res"},{"key":"R121-11-20210202","first-page":"2318","article-title":"Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate.","volume":"26","author":"Cantatore","year":"1999","journal-title":"J Rheumatol"},{"key":"R122-11-20210202","first-page":"1117","article-title":"Effects of bisphosphonates on interleukin 1, tumor necrosis factor alpha, and beta 2 microglobulin in rheumatoid arthritis.","volume":"23","author":"Cantatore","year":"1996","journal-title":"J Rheumatol"},{"key":"R123-11-20210202","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.1780390915","article-title":". Phagocytic lining cells determine local expression of inflammation in type II collagen-induced arthritis.","volume":"39","author":"van Lent","year":"1996","journal-title":"Arthritis Rheum"},{"key":"R124-11-20210202","first-page":"1280","article-title":". Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis.","volume":"30","author":"Matsuo","year":"2003","journal-title":"J Rheumatol"},{"key":"R125-11-20210202","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/03009749509100906","article-title":". Role of macrophage-like synovial lining cells in localization and expression of experimental arthritis.","volume":"101","author":"van Lent","year":"1995","journal-title":"Scand J Rheumatol Suppl"},{"key":"R126-11-20210202","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s00198-005-0037-2","article-title":". Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.","volume":"17","author":"Lems","year":"2006","journal-title":"Osteoporos Int"},{"key":"R127-11-20210202","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1002\/art.23988","article-title":". Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial.","volume":"58","author":"Mawatari","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R128-11-20210202","first-page":"407","article-title":". Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.","volume":"35","author":"Morishita","year":"2008","journal-title":"J Rheumatol"},{"key":"R129-11-20210202","first-page":"1732","article-title":". Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis.","volume":"31","author":"Cremers","year":"2004","journal-title":"J Rheumatol"},{"key":"R130-11-20210202","first-page":"474","article-title":". Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis.","volume":"30","author":"Hasegawa","year":"2003","journal-title":"J Rheumatol"},{"key":"R131-11-20210202","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF03324436","article-title":". Single infusion of neridronate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonate) in patients with active rheumatoid arthritis: effects on disease activity and bone resorption markers.","volume":"14","author":"Mazzantini","year":"2002","journal-title":"Aging Clin Exp Res"},{"key":"R132-11-20210202","first-page":"21","article-title":". Alendronate decreases TRACP 5b activity in osteoarthritic bone.","volume":"13","author":"Mehlhorn","year":"2008","journal-title":"Eur J Med Res"},{"key":"R133-11-20210202","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/rheumatology\/kep084","article-title":". Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid.","volume":"48","author":"Rossini","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R134-11-20210202","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/rheumatology\/kel213","article-title":". A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients.","volume":"46","author":"Buckland-Wright","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R135-11-20210202","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1002\/art.22160","article-title":". Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.","volume":"54","author":"Bingham","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R136-11-20210202","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.joca.2007.10.002","article-title":". Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial.","volume":"16","author":"Garnero","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"R137-11-20210202","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s11926-010-0122-1","article-title":"Osteoporosis in ankylosing spondylitis.","volume":"12","author":"Magrey","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"R138-11-20210202","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/BOR.0b013e328133f57b","article-title":"Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis.","volume":"19","author":"Toussirot","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"R139-11-20210202","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/10717540590952663","article-title":"Veena. Formulation and evaluation of Alendronate Sodium gel for the treatment of bone resorptive lesions in Periodontitis.","volume":"12","author":"Reddy","year":"2005","journal-title":"Drug Deliv"},{"key":"R140-11-20210202","first-page":"5","article-title":"The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial).","volume":"5","author":"El-Shinnawi","year":"2003","journal-title":"J Int Acad Periodontol"},{"key":"R141-11-20210202","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1902\/jop.2005.76.7.1113","article-title":". Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study.","volume":"76","author":"Lane","year":"2005","journal-title":"J Periodontol"},{"key":"R142-11-20210202","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0765.2010.01306.x","article-title":"Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6.","volume":"46","author":"Tipton","year":"2011","journal-title":"J Periodontal Res"},{"key":"R143-11-20210202","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1254\/jphs.FM0070272","article-title":". Pharmacological topics of bone metabolism: a novel bisphosphonate for the treatment of periodontitis.","volume":"106","author":"Shinoda","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"R144-11-20210202","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.4049\/jimmunol.173.5.3119","article-title":". CD4CD25bright T cells in human intestinal lamina propria as regulatory cells.","volume":"173","author":"Makita","year":"2004","journal-title":"J Immunol"},{"key":"R145-11-20210202","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.4049\/jimmunol.0711823","article-title":". RANK-RANKL signaling pathway is critically involved in the function of CD4CD25 regulatory T cells in chronic colitis.","volume":"182","author":"Totsuka","year":"2009","journal-title":"J Immunol"},{"key":"R146-11-20210202","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1365-2036.2003.01794.x","article-title":". A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohns disease.","volume":"18","author":"Bartram","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R147-11-20210202","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/gast.2000.16518","article-title":". Alendronate increases lumbar spine bone mineral density in patients with Crohns disease.","volume":"119","author":"Haderslev","year":"2000","journal-title":"Gastroenterology"},{"key":"R149-11-20210202","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jbspin.2009.05.017","article-title":"SAPHO syndrome in an adult with ulcerative colitis responsive to intravenous pamidronate.","volume":"77","author":"Siau","year":"2010","journal-title":"Joint Bone Spine"},{"key":"R150-11-20210202","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2169\/internalmedicine.48.2005","article-title":". Alendronate improves low bone mineral density induced by steroid therapy in Crohns disease.","volume":"48","author":"Tsujikawa","year":"2009","journal-title":"Intern Med"},{"key":"R151-11-20210202","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.arth.2009.07.029","article-title":"Effect of alendronate on pseudomembrane cytokine expression in patients with aseptic osteolysis.","volume":"25","author":"Holt","year":"2010","journal-title":"J Arthroplasty"},{"key":"R152-11-20210202","first-page":"276","article-title":"RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis.","volume":"4","author":"Ritchlin","year":"2004","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"R153-11-20210202","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jor.20748","article-title":". Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty.","volume":"27","author":"Arabmotlagh","year":"2009","journal-title":"J Orthop Res"},{"key":"R154-11-20210202","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00774-006-0743-7","article-title":". Alendronate inhibits periprosthetic bone loss around uncemented femoral components.","volume":"25","author":"Nishioka","year":"2007","journal-title":"J Bone Miner Metab"},{"key":"R155-11-20210202","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00223-002-1022-9","article-title":". Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients.","volume":"71","author":"Soininvaara","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"R156-11-20210202","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bone.2011.01.009","article-title":"Bisphosphonates in orthopedic applications.","volume":"49","author":"Wilkinson","year":"2011","journal-title":"Bone"},{"key":"R157-11-20210202","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.injury.2011.03.061","article-title":"Systemic administration of pharmacological agents and bone repair: what can we expect.","volume":"42","author":"Bukata","year":"2011","journal-title":"Injury"},{"key":"R158-11-20210202","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2003.07639.x","article-title":". Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.","volume":"98","author":"Guanabens","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R159-11-20210202","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0168-8278(97)80048-7","article-title":". Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study.","volume":"26","author":"Wolfhagen","year":"1997","journal-title":"J Hepatol"},{"key":"R160-11-20210202","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.20866","article-title":". Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial.","volume":"42","author":"Zein","year":"2005","journal-title":"Hepatology"},{"key":"R161-11-20210202","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bone.2009.11.034","article-title":"The successful use of pamidronate in an 11-year-old girl with complex regional pain syndrome: response to treatment demonstrated by serial peripheral quantitative computerised tomographic scans.","volume":"46","author":"Simm","year":"2010","journal-title":"Bone"},{"key":"R162-11-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejpain.2008.03.005","article-title":". Biphosphonates for the therapy of complex regional pain syndrome I-systematic review.","volume":"13","author":"Brunner","year":"2009","journal-title":"Eur J Pain"},{"key":"R163-11-20210202","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1002\/art.20591","article-title":". Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity.","volume":"50","author":"Manicourt","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R164-11-20210202","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/ard.56.3.201","article-title":". Bisphosphonate therapy of reflex sympathetic dystrophy syndrome.","volume":"56","author":"Adami","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"R165-11-20210202","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1526-4637.2004.04038.x","article-title":"Efficacy of pamidronate in complex regional pain syndrome type I.","volume":"5","author":"Robinson","year":"2004","journal-title":"Pain Med"},{"key":"R166-11-20210202","doi-asserted-by":"crossref","first-page":"96","DOI":"10.14310\/horm.2002.1226","article-title":"Bisphosphonate-associated adverse events.","volume":"8","author":"Papapetrou","year":"2009","journal-title":"Hormones (Athens)"},{"key":"R167-11-20210202","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/11585470-000000000-00000","article-title":"Safety of long-term bisphosphonate therapy for the management of osteoporosis.","volume":"71","author":"Lewiecki","year":"2011","journal-title":"Drugs"},{"key":"R169-11-20210202","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2010.1098","article-title":". Exposure to oral bisphosphonates and risk of esophageal cancer.","volume":"304","author":"Cardwell","year":"2010","journal-title":"JAMA"},{"key":"R170-11-20210202","doi-asserted-by":"crossref","first-page":"c4444","DOI":"10.1136\/bmj.c4444","article-title":". Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.","volume":"341","author":"Green","year":"2010","journal-title":"BMJ"},{"key":"R171-11-20210202","first-page":"619","article-title":"What is the optimal duration of bisphosphonate therapy Cleve Clin J Med.","volume":"78","author":"Ott","year":"2011","journal-title":""},{"key":"R172-11-20210202","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14740338.2.4.421","article-title":"Gastrointestinal side effects of drugs.","volume":"2","author":"Makins","year":"2003","journal-title":"Expert Opin Drug Saf"},{"key":"R173-11-20210202","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1196\/annals.1365.036","article-title":"Bisphosphonates.","volume":"1092","author":"Lambrinoudaki","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"R174-11-20210202","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":". Esophagitis associated with the use of alendronate.","volume":"335","author":"de Groen","year":"1996","journal-title":"N Engl J Med"},{"key":"R175-11-20210202","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1572-0241.2000.01835.x","article-title":". Upper gastrointestinal toxicity of alendronate.","volume":"95","author":"Lowe","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R176-11-20210202","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc0808738","article-title":"Reports of esophageal cancer with oral bisphosphonate use.","volume":"360","author":"Wysowski","year":"2009","journal-title":"N Engl J Med"},{"key":"R178-11-20210202","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":". Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"R179-11-20210202","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity.","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"R181-11-20210202","first-page":"534","article-title":"Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease.","volume":"29","author":"Bergner","year":"2006","journal-title":"Onkologie"},{"key":"R182-11-20210202","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0002-9394(02)01840-8","article-title":"Scleritis and other ocular side effects associated with pamidronate disodium.","volume":"135","author":"Fraunfelder","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R184-11-20210202","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/IAE.0b013e31816576ef","article-title":"Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.","volume":"28","author":"French","year":"2008","journal-title":"Retina"},{"key":"R185-11-20210202","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","article-title":". The acute-phase response after bisphosphonate administration.","volume":"41","author":"Adami","year":"1987","journal-title":"Calcif Tissue Int"},{"key":"R186-11-20210202","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1078155207080806","article-title":"Significance and impact of bisphosphonate-induced acute phase responses.","volume":"13","author":"Olson","year":"2007","journal-title":"J Oncol Pharm Pract"},{"key":"R187-11-20210202","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jbmr.5650100617","article-title":". Interleukin-6 and the acute phase response during treatment of patients with Pagets disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate.","volume":"10","author":"Schweitzer","year":"1995","journal-title":"J Bone Miner Res"},{"key":"R188-11-20210202","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":". The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins.","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"R189-11-20210202","first-page":"1399","article-title":". The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women.","volume":"76","author":"Harris","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"R190-11-20210202","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1445-5994.2007.01580.x","article-title":"Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid.","volume":"38","author":"Chennuru","year":"2008","journal-title":"Intern Med J"},{"key":"R191-11-20210202","first-page":"144","article-title":". Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.","volume":"7","author":"Bock","year":"2007","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"R192-11-20210202","first-page":"346","article-title":"Alendronate and risedronate: reports of severe bone, joint, and muscle pain.","volume":"165","author":"Wysowski","year":"2005","journal-title":"Arch Intern Med"},{"key":"R193-11-20210202","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1210\/jc.2001-011814","article-title":". Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism.","volume":"87","author":"Nakchbandi","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R194-11-20210202","first-page":"3448","article-title":"Cytokines in primary hyperparathyroidismfactors that matter.","volume":"81","author":"Silverberg","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"R195-11-20210202","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14219\/jada.archive.2008.0016","article-title":"Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people.","volume":"139","author":"Cartsos","year":"2008","journal-title":"J Am Dent Assoc"},{"key":"R197-11-20210202","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1755-1536-3-6","article-title":". A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis.","volume":"3","author":"Scheper","year":"2010","journal-title":"Fibrogenesis Tissue Repair"},{"key":"R198-11-20210202","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative corrected review: bisphosphonates and osteonecrosis of the jaws.","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"R199-11-20210202","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":". Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"R200-11-20210202","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMc076132","article-title":"Alendronate and atrial fibrillation.","volume":"356","author":"Cummings","year":"2007","journal-title":"N Engl J Med"},{"key":"R201-11-20210202","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00198-011-1608-z","article-title":". Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.","volume":"23","author":"Rhee","year":"2012","journal-title":"Osteoporos Int"},{"key":"R202-11-20210202","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archinte.168.8.826","article-title":". Use of alendronate and risk of incident atrial fibrillation in women.","volume":"168","author":"Heckbert","year":"2008","journal-title":"Arch Intern Med"},{"key":"R203-11-20210202","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMe1003064","article-title":"Evolving data about subtrochanteric fractures and bisphosphonates.","volume":"362","author":"Shane","year":"2010","journal-title":"N Engl J Med"},{"key":"R204-11-20210202","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.","volume":"358","author":"Lenart","year":"2008","journal-title":"N Engl J Med"},{"key":"R205-11-20210202","first-page":"179","article-title":". Severe acute hepatitis induced by alendronate in French.","volume":"26","author":"Carrere","year":"2002","journal-title":"Gastroenterol Clin Biol"},{"key":"R206-11-20210202","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJM200008033430512","article-title":"Liver damage due to alendronate.","volume":"343","author":"Halabe","year":"2000","journal-title":"N Engl J Med"},{"key":"R207-11-20210202","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/j.amjmed.2006.04.032","article-title":"Risedronate-induced Hepatitis.","volume":"120","author":"Phillips","year":"2007","journal-title":"Am J Med"},{"key":"R208-11-20210202","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00198-007-0323-2","article-title":"Hepatotoxicity induced by alendronate therapy.","volume":"18","author":"Yanik","year":"2007","journal-title":"Osteoporos Int"},{"key":"R209-11-20210202","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1902\/jop.2002.73.3.251","article-title":". Disodium chlodronate prevents bone resorption in experimental periodontitis in rats.","volume":"73","author":"Alencar","year":"2002","journal-title":"J Periodontol"},{"key":"R210-11-20210202","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1902\/jop.2002.73.5.479","article-title":"Effects of topical administration of clodronate on alveolar bone resorption in rats with experimental periodontitis.","volume":"73","author":"Mitsuta","year":"2002","journal-title":"J Periodontol"},{"key":"R211-11-20210202","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0765.1994.tb01088.x","article-title":". Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys.","volume":"29","author":"Weinreb","year":"1994","journal-title":"J Periodontal Res"},{"key":"R212-11-20210202","first-page":"714","article-title":". An open study of pamidronate in the treatment of refractory ankylosing spondylitis.","volume":"25","author":"Maksymowych","year":"1998","journal-title":"J Rheumatol"},{"key":"R213-11-20210202","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3109\/10428194.2011.554586","article-title":"The role of bisphosphonate therapy in the global management of multiple myeloma.","volume":"52","author":"Gertz","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R214-11-20210202","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/annonc\/mdp378","article-title":". Antitumoral effect of the bisphosphonate zoledronic acid against visceral metastases in an adrenocortical cancer patient.","volume":"20","author":"Boudou-Rouquette","year":"2009","journal-title":"Ann Oncol"},{"key":"R215-11-20210202","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1517\/14656566.2010.523699","article-title":"The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.","volume":"11","author":"Tonyali","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"R216-11-20210202","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1902\/jop.1995.66.3.211","article-title":". Alendronate treatment of naturally-occurring periodontitis in beagle dogs.","volume":"66","author":"Reddy","year":"1995","journal-title":"J Periodontol"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-201205000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:02:04Z","timestamp":1642204924000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201205000-00011"}},"subtitle":["Focus on Inflammation and Bone Loss"],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":200,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e318247148f","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}